Publication

Hepatocellular carcinoma and the Fontan circulation: Clinical presentation and outcomes

Journal Paper/Review - Aug 21, 2020

Units
PubMed
Doi

Citation
Possner M, Oechslin E, Kay W, Norris M, Dillman J, Trout A, Anwar N, Hoskoppal A, Broering D, Bzeizi K, Moe T, Wagenaar L, Walker N, Gordon-Walker T, Egbe A, Poterucha J, Warnes C, Connolly H, Ginde S, Clift P, Kogon B, Book W, Veldtman G. Hepatocellular carcinoma and the Fontan circulation: Clinical presentation and outcomes. Int J Cardiol 2020; 322:142-148.
Type
Journal Paper/Review (English)
Journal
Int J Cardiol 2020; 322
Publication Date
Aug 21, 2020
Issn Electronic
1874-1754
Pages
142-148
Brief description/objective

BACKGROUND
Fontan-associated liver disease (FALD) is universal in patients with a Fontan circulation. Hepatocellular carcinoma (HCC) is one of its severe expressions, and, though rare, frequently fatal. The purpose of this study was to describe the clinical presentation, risk factors, and outcomes of HCC in patients with a Fontan circulation.

METHODS
A multicenter case series of Fontan patients with a diagnosis of HCC formed the basis of this study. The case series was extended by published cases and case reports. Clinical presentation, tumor characteristics, laboratory and hemodynamic findings as well as treatment types and outcomes, were described.

RESULTS
Fifty-four Fontan patients (50% female) with a diagnosis of HCC were included. Mean age at HCC diagnosis was 30 ± 9.4 years and mean duration from Fontan surgery to HCC diagnosis was 21.6 ± 7.4 years. Median HCC size at the time of diagnosis was 4 cm with a range of 1 to 22 cm. The tumor was located in the right hepatic lobe in 65% of the patients. Fifty-one percent had liver cirrhosis at the time of HCC diagnosis. Fifty percent of the patients had no symptoms related to HCC and alpha-fetoprotein was normal in 26% of the cases. Twenty-six patients (48%) died during a median follow-up duration of 10.6 (range 1-50) months.

CONCLUSIONS
HCC in Fontan patients occurs at a young age with a 1-year survival rate of only 50%. Meticulous liver surveillance is crucial to detect small tumors in the early stage.